Skip to content

Study · Case report or series · n = 1 · 2018

5 results

Dermatologic toxicity from novel therapy using antimicrobial peptide LL-37 in melanoma: A detailed examination of the clinicopathologic features.

Dolkar T, Trinidad CM, Nelson KC, Amaria RN, Nagarajan P, Torres-Cabala CA, Ivan D, Prieto VG, Tetzlaff MT, Curry JL, Aung PP

Journal of cutaneous pathology16 May 2018Cited by 15 (Europe PMC)

PMID29665030 (opens in a new tab)DOI10.1111/cup.13262 (opens in a new tab)PepBankPUB-29665030
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In a woman with stage IIIC melanoma, 8 weekly LL‑37 injections were followed by interval clinical shrinkage of injected lesions.

    In plain wordsIn one woman with melanoma, injected skin lesions shrank during 8 weekly LL‑37 injections.

    Peptide
    LL-37
    Outcome
    DecreaseShrinkage of injected lesions
    Study

    n = 1

    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated · intratumoral injection · 8 weekly injectionsAs given in this study (human).

    Source sentences

    Summary
    She received a total of 8 weekly LL-37 injections, with interval clinical shrinkage of injected lesions.
    1 context sentence
    Summary · context
    We report dermatologic toxicity in a 63-year-old woman with stage IIIC melanoma of the right calf and inguinal lymph nodes.
  2. 02HumanCase report or seriesSafety outcome

    In a woman with melanoma, multiple verrucous papules and a vesiculo-bullous lesion appeared on the trunk and extremities about 45 days after LL‑37 therapy began.

    In plain wordsIn one woman with melanoma, new skin growths and a blister appeared about 45 days after starting LL‑37 injections.

    Peptide
    LL-37
    Outcome
    IncreaseNew verrucous papules and vesiculo-bullous lesion
    Study

    n = 1

    Outcome group
    Adverse events · Skin and wound
    Studied dose
    Dose not stated · intratumoral injection · 8 weekly injectionsAs given in this study (human).

    Source sentences

    Summary
    However, approximately 45 days after initiation of this therapy, she presented with multiple verrucous papules and a vesiculo-bullous lesion on the trunk and extremities.
    1 context sentence
    Summary · context
    We report dermatologic toxicity in a 63-year-old woman with stage IIIC melanoma of the right calf and inguinal lymph nodes.
  3. 03HumanCase report or seriesSafety outcome

    In a woman with melanoma given LL‑37, 11 of 12 skin biopsies showed a lichenoid inflammatory infiltrate with eosinophils and an atypical verrucous squamous epithelial proliferation.

    In plain wordsIn one woman with melanoma given LL‑37, most skin biopsies showed inflammation and abnormal skin cell growth.

    Peptide
    LL-37
    Outcome
    Not applicableHistology of skin lesions
    Study

    n = 1

    Outcome group
    Adverse events · Skin and wound
    Studied dose
    Dose not stated · intratumoral injection · 8 weekly injectionsAs given in this study (human).

    Measurements

    Biopsies with similar features
    11 of 12
    skin biopsies

    Source sentences

    Summary
    Histologically, 11 of the total 12 skin biopsies showed similar histopathologic features, with a prominent lichenoid inflammatory infiltrate admixed with eosinophils and an overlying atypical squamous epithelial proliferation with verrucous and keratoacanthoma-like features and varying degrees of keratinocytic atypia.
    1 context sentence
    Summary · context
    We report dermatologic toxicity in a 63-year-old woman with stage IIIC melanoma of the right calf and inguinal lymph nodes.
  4. 04HumanCase report or seriesSafety outcome

    In a woman with melanoma given LL‑37, a majority of lesions did not show spongiosis (11/12).

    In plain wordsIn one woman with melanoma given LL‑37, most skin lesions did not show a certain fluid swelling pattern.

    Peptide
    LL-37
    Outcome
    Not applicableAbsence of spongiosis in lesions
    Study

    n = 1

    Outcome group
    Adverse events · Skin and wound
    Studied dose
    Dose not stated · intratumoral injection · 8 weekly injectionsAs given in this study (human).

    Source sentences

    Summary
    Interestingly, a majority of the lesions did not show spongiosis (11/12).
    1 context sentence
    Summary · context
    We report dermatologic toxicity in a 63-year-old woman with stage IIIC melanoma of the right calf and inguinal lymph nodes.
  5. 05HumanCase report or seriesSafety outcome

    In a woman with melanoma, all skin lesions resolved within 2 months of stopping LL‑37 injections.

    In plain wordsIn one woman with melanoma, the skin lesions went away within 2 months after LL‑37 injections stopped.

    Peptide
    LL-37
    Outcome
    DecreaseResolution of lesions after stopping LL-37
    Study

    n = 1

    Outcome group
    Adverse events · Skin and wound
    Studied dose
    Dose not stated · intratumoral injection · 8 weekly injectionsAs given in this study (human).

    Source sentences

    Summary
    All lesions resolved within 2 months of cessation of LL-37 injection therapy.
    1 context sentence
    Summary · context
    We report dermatologic toxicity in a 63-year-old woman with stage IIIC melanoma of the right calf and inguinal lymph nodes.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:57 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.